Randomized trial of the ForeseeHome monitoring device for early detection of neovascular age-related macular degeneration. The HOme Monitoring of the Eye (HOME) study design - HOME Study report number 1.
暂无分享,去创建一个
Emily Y. Chew | Amitha Domalpally | Ronald P. Danis | Judy E. Kim | Michael J. Elman | Jeffrey S. Heier | S. Bressler | E. Chew | M. Elman | R. Danis | T. Clemons | A. Domalpally | J. Heier | Traci E. Clemons | Susan B. Bressler | R. Garfinkel | Richard A. Garfinkel
[1] G Westheimer,et al. Editorial: Visual acuity and hyperacuity. , 1975, Investigative ophthalmology.
[2] Gerald Liew,et al. Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.
[3] F. Ferris,et al. Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.
[4] Usha Chakravarthy,et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. , 2012, Ophthalmology.
[5] J. Vander,et al. Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration , 2008 .
[6] D. Fong,et al. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. , 2010, Ophthalmology.
[7] Amitha Domalpally,et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. , 2014, Ophthalmology.
[8] A D Négrel,et al. 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies , 2004, Ophthalmic epidemiology.
[9] R. Klein,et al. Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.
[10] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[11] Glenn J Jaffe,et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. , 2013, Ophthalmology.
[12] D. Roth,et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. , 2011, Ophthalmology.
[13] J. R. Ferencz,et al. TOWARD EARLIER DETECTION OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION: Multicenter Evaluation of a Preferential Hyperacuity Perimeter Designed as a Home Device , 2010, Retina.
[14] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[15] TIME TO FIRST TREATMENT: The Significance of Early Treatment of Exudative Age-related Macular Degeneration , 2012, Retina.
[16] Benita J. O’Colmain,et al. Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.
[17] J. Vander,et al. Ranibizumab for Predominantly Classic Neovascular Age-related Macular Degeneration: Subgroup Analysis of First-year ANCHOR Results , 2008 .
[18] Chris A. Johnson,et al. A COMPUTERIZED METHOD OF VISUAL ACUITY TESTING: ADAPTATION OF THE EARLY TREATMENT OF DIABETIC RETINOPATHY STUDY TESTING PROTOCOL , 2003 .